SEC Form 4 · accession 0001209191-18-049721
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dimitri E. Grigoriadis
Officer — Chief Research Officer
Period of report
Sep 4, 2018
Accepted (ET)
Sep 5, 2018 · 8:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 4, 2018 | M | 13,632 | $8.66 | A | 96,574 | D | |
| Common Stock | Sep 4, 2018 | M | 11,037 | $8.65 | A | 107,611 | D | |
| Common Stock | Sep 4, 2018 | M | 5,978 | $19.59 | A | 113,589 | D | |
| Common Stock | Sep 4, 2018 | M | 2,102 | $32.99 | A | 115,691 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF1 | $8.66 | Sep 4, 2018 | M | 13,632 | A | — | Jan 12, 2022 | Common Stock | 13,632 | 0 | D |
| Incentive Stock OptionF2 | $8.65 | Sep 4, 2018 | M | 11,037 | A | — | Jan 10, 2023 | Common Stock | 11,037 | 0 | D |
| Incentive Stock OptionF3 | $19.59 | Sep 4, 2018 | M | 5,978 | A | — | Jan 16, 2024 | Common Stock | 5,978 | 0 | D |
| Incentive Stock OptionF4 | $32.99 | Sep 4, 2018 | M | 2,102 | A | — | Feb 3, 2025 | Common Stock | 2,102 | 2,710 | D |
Explanation of responses
- F1Option granted January 12, 2012 and vested monthly over four years.
- F2Option granted January 10, 2013 and vested monthly over four years.
- F3Option granted January 16, 2014 and vested monthly over four years.
- F4Option granted February 3, 2015 and vests monthly over four years.